Press Releases Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Delayed Nasdaq Other stock markets 03:07:22 2024-04-29 pm EDT			5-day change	1st Jan Change
0.2851 ^USD	-6.80%		-3.45%	-7.73%

Apr. 23	Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	CI
Mar. 28	Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	Apr. 23	AQ
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Apr. 11	AQ
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	Mar. 28	AQ
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	Mar. 21	AQ
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	Feb. 22	AQ
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	AQ
Daré Bioscience Announces Executive Team and Board of Directors Changes	Jan. 26	AQ
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development	Jan. 17	AQ
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases	Jan. 04	AQ
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure	Dec. 26	AQ
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study	Dec. 20	AQ
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study	Dec. 13	AQ
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause	Dec. 07	AQ
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Dec. 04	AQ
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs	Nov. 20	AQ
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting	Nov. 13	AQ
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update	Nov. 09	AQ
Daré Bioscience to Participate in Three November Conferences	Nov. 06	AQ
Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023	Nov. 02	AQ
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program	Nov. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Press Releases

Filters